Plus Therapeutics downgraded to Hold from Buy at D. Boral Capital

D. Boral Capital downgraded Plus Therapeutics (PSTV) to Hold from Buy ahead of the company’s newly announced 1-for-25 reverse stock split that becomes effective April 2. While the split to preserve Nasdaq listing compliance does not alter the company’s underlying enterprise value, reverse splits in small-cap biotech “typically signal capital market strain, often pressure trading liquidity, and can take meaningful time to repair the shareholder base,” the analyst tells investors.